A focused update to the 2019 NLA scientific statement on use of lipoprotein(a) in clinical practice

•Lp(a) level should be measured at least once in all adults.•Lp(a) levels represent a continuum of risk, not a risk threshold at a dichotomous cutpoint.•Risk classification by Lp(a) level ranges from low (

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of clinical lipidology 2024-05, Vol.18 (3), p.e308-e319
Hauptverfasser:	Koschinsky, Marlys L., Bajaj, Archna, Boffa, Michael B., Dixon, Dave L., Ferdinand, Keith C., Gidding, Samuel S., Gill, Edward A., Jacobson, Terry A., Michos, Erin D., Safarova, Maya S., Soffer, Daniel E., Taub, Pam R., Wilkinson, Michael J., Wilson, Don P., Ballantyne, Christie M.
Format:	Artikel
Sprache:	eng
Schlagworte:	Cardiovascular disease Cardiovascular Diseases - blood Cardiovascular Diseases - prevention & control Guidelines Humans Hypolipidemic Agents - therapeutic use Lipoprotein(a) Lipoprotein(a) - blood Prevention Risk assessment Risk Factors Scientific statements Treatment practice
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	•Lp(a) level should be measured at least once in all adults.•Lp(a) levels represent a continuum of risk, not a risk threshold at a dichotomous cutpoint.•Risk classification by Lp(a) level ranges from low (
ISSN:	1933-2874 1876-4789
DOI:	10.1016/j.jacl.2024.03.001